

# INSTRUCTIONS FOR AUTHORS

## **1. INTRODUCTION**

Anales de la Real Academia Nacional de Farmacia Journal will publish papers in all areas of pharmaceutical sciences. The Journal publishes peer-reviewed short communications, mini- and full-length review articles and research papers written in Spanish or English. Opinion Pieces, Scientific News and other topics can also be considered for publication.

Authors interested in editing a single issue in an emerging topic of pharmacology or drug design may submit their proposal to the Editor-in-Chief at: [antonio@ranf.com](mailto:antonio@ranf.com) for its consideration.

For proposals to publish conference proceedings in this journal, please contact us at email: [antonio@ranf.com](mailto:antonio@ranf.com)

The editors reserve the right to introduce minor changes in the manuscript to adjust them to the norms of the Journal or to improve the style.

## **2. EDITORIAL POLICIES**

### **2.1. Permission for reproduction**

Published/reproduced material should not be included unless written permission has been obtained from the copyright holder, which should be forwarded to the Editorial Office in case of acceptance of the article for publication.

### **2.2. Reviewing and promptness of publication**

All manuscripts submitted for publication will be immediately subjected to peer-reviewing, usually by the members of the Editorial Advisory Board and a number of external referees.

All the peer-reviewing process will be conducted via Internet to facilitate rapid reviewing of the submitted manuscripts. The Editorial Office will provide information about the acceptance, revisión or rejection in a maximal of 30 days after the submission.

### **2.3. Language and editing**

Manuscripts submitted containing many Spanish or English grammar or typographical errors will not be published and will be returned to the authors for editing.

### **2.4. Proof corrections**

Authors will receive the galley proofs of their accepted paper before publication. To avoid delays in publication, proofs should be checked immediately for typographical errors and returned within 48 hours. Major changes are not acceptable at the proof stage. If unable to send

corrections within 48 hours due to any reasons, the author(s) must at least send an acknowledgement when receiving the galley proofs or the article will be published exactly as received. The publishers will not be responsible for any error occurring in the published manuscript in this regard.

The corresponding author should be clearly designated in the submitted manuscript and their complete address, business telephone and fax numbers and e-mail address must be stated to receive correspondence and galley proofs. The corresponding author will be responsible of the revised version of the manuscript incorporating all the corrections in the re-submitted manuscript after the approval of all the co-authors of the manuscript.

## **2.5. Copyright**

Authors who publish in *Anales de la Real Academia Nacional de Farmacia* journals will transfer the copyright to their work to Real Academia Nacional de Farmacia (RANF). Submission of a manuscript to the journal implies that all authors have read and agreed to the content of the Copyright Form that is displayed in the online application. It is a condition of publication that manuscripts submitted to this journal have not been published and will not be simultaneously submitted or published elsewhere. Plagiarism is strictly forbidden, and by submitting the article for publication the authors agree that the publishers have the legal right to take appropriate action against the authors, if plagiarism or fabricated information is discovered. By online submitting a manuscript the authors agree that the copyright of their article is transferred to the publishers when the article is accepted for publication. Once submitted to the journal, the author will not withdraw their manuscript at any stage prior to publication.

## **2.6. Self-archiving**

The authors may post the first draft of an article submitted for publication on their personal web pages, repositories of their institution or any noncommercial repository for personal, internal use of the institution or academic publication.

Authors can deposit the accepted version of the article reviewed by peers in their personal websites, repository of your institution or any noncommercial repository as PMC or arXiv.

In accordance with the agreement of copyright, RANF does not allow to file the final published version of the manuscript.

## **2.7. E-Pub**

RANF is pleased to offer the electronic publication of papers after the publication of the corresponding issue.

## **2.8. Disclaimer**

Articles appearing in this journal may contain statements, opinions, and information that have errors in facts, figures, or interpretation. Accordingly, RANF Publishers, the editors and their employees are not responsible or liable for the use of any such inaccurate or misleading data, opinion or information contained in articles of the E-Pub or online.

### **2.9. Standard Protocol on Approvals, Registrations, Patient Consents & Animal Protection**

All clinical investigations must be conducted according to the Declaration of Helsinki principles. For all manuscripts reporting data from studies involving human participants, formal review and approval by an appropriate institutional review board or ethics committee is required. For research involving animals, the authors should indicate whether the procedures followed were in accordance with the standards set forth in the eighth edition of Guide for the Care and Use of Laboratory Animals ([grants.nih.gov/grants/olaw/Guide-for-the-care-and-use-of-Laboratory-animals/](http://grants.nih.gov/grants/olaw/Guide-for-the-care-and-use-of-Laboratory-animals/); published by the National Academy of Sciences, The National Academies Press, Washington, D.C.).

A specific declaration of such approval must be made in the copyright letter and in a stand-alone paragraph at the end of the **Methods** section especially in the case of human studies where inclusion of a statement regarding obtaining the written informed consent from each subject or subject's guardian is compulsory. The original should be retained by the guarantor or corresponding author. Editors may request to provide the original forms by fax or email.

### **2.10. Authentication of Cell Lines**

RANF recommends that all cell lines to be authenticated prior to submitting a paper for review. Authors are therefore required to provide authentication of the origin and identity of the cells by performing cell profiling either in their own laboratory or by outsourcing an approved laboratory or cell bank. Authentication is required when a new line is established or acquired, before freezing a cell line, if the performance of the line is not consistent or results are unexpected, if using more than one cell line, and before publication of the study.

The cell lines profile should be cross-checked with the profile of the donor tissue of other continuous cell lines such as provided by the authentic data bank such as [www.dsmz.de/fp/cgi-bin/str.html](http://www.dsmz.de/fp/cgi-bin/str.html), ATCC®, etc.

## **3. ONLINE MANUSCRIPT SUBMISSION**

The full manuscript has to be submitted online via RANF OJS System at:

<http://analesranf.com/index.php/aranf/login>

Manuscripts must be submitted by one of the authors of the manuscript, and should not be submitted by anyone on their behalf. The principal/corresponding author will be required to

read and accept a Copyright Form when sending the manuscript online, on behalf of all the co-authors (if any). The author(s) will confirm in the sending online that the manuscript (or any part of it) has not been published previously or is not under consideration for publication elsewhere.

For all online submissions, you must provide a single electronic copy of the complete article in MS Word file. Include embedded all the figures/illustrations/tables/chemical structures, etc. In addition, figures/illustrations in TIFF or JPEG format, and the chemical structures in ChemDraw (CDX) in separate files, will also be sent as supplementary material.

It is imperative that before submission, authors should carefully proofread the files for special characters, mathematical symbols, Greek letters, equations, tables, references and images, to ensure that they appear in proper format.

References, figures, tables, chemical structures etc. should be referred to in the text at the appropriate place where they have been first discussed. Figure legends/captions should also be provided.

## **4. MANUSCRIPT LENGTH, STYLE AND FORMAT**

### **4.1. Length**

#### **4.1.a. Scientific News**

Scientific News are, mainly, comments about an article of relevant research in the pharmaceutical sciences.

#### **4.1.b. Opinion Pieces**

Opinion Pieces are specific comments raised by a scientific matter in pharmaceutical sciences. Unlike the editorial, article is signed and represents the particular opinion of its author. Opinion Pieces should be no longer than 4000 words inclusive of all the references, and should contain no more than ten Figures. These type of manuscript should follow the rules pertaining to the preparation, text-formatting and submission of Research Articles for this Journal. No abstract is required.

#### **4.1.c. Short Communications**

Short Communications are intended for preliminary reports of original, significant research results that are limited in scope and, thus, do not warrant publication in the form of a regular Research Article. Communications should be no longer than 4000 words inclusive of all the references, and should contain no more than two Figures (which may be multi-panel) and/or Tables. These type of manuscript should follow the rules pertaining to the preparation, text-formatting and submission of Research Articles for this Journal.

#### **4.1.d. Mini-Reviews**

Mini-reviews should be 3000-6000 words excluding figures, structures, photographs, schemes, tables etc.

#### **4.1.e Full-Length Reviews**

Full-length reviews should be 8000-40000 words excluding figures, structures, photographs, schemes, tables etc.

#### **4.1.f. Research Articles**

Research articles should be 4000-8000 words excluding figures, structures, photographs, schemes, tables etc.

There is no restriction on the number of figures, tables or additional files e.g. video clips, animation and datasets, that can be included with each article.

### **4.2. Style and format**

**Font:** Times New Roman

**Font Size:** 12pto

**Font Color:** Black

**Spacing:** Double-spaced

**Paragraphs:** Justified

**Tables, Schemes, Figures and captions:** placed in the text, as close as possible to the first citation.

**Figures:** numbered with Arabic numerals.

**Maps:** insert as Supplementary Material

**Chemical Structures in:** \*.cdx (ChemDraw).

**Graphics in:** JPG, TIFF, PNG in a resolution of 900-1200 dpi.

## **5. MANUSCRIPT PREPARATION**

The manuscript should be written in Spanish or English in a clear and direct style. All pages must be numbered sequentially, facilitating in the reviewing and editing of the manuscript.

### **5.1. Manuscript sections for papers**

Manuscripts may be divided into the following sections:

Title page. Abstract. Keywords. Text Main and Organization. List of Abbreviations (if any). Conflict of Interest (disclaimer). Acknowledgements. References. Appendices.

### **5.2. Title page (fFirst page)**

Title page should include paper title, author(s) full name and affiliation and corresponding author(s) names complete affiliation/address, phone, fax, and email.

The title of the article should be precise and brief and must not be more than 120 characters. Authors should avoid the use of non-standard abbreviations. The title should be written in type paragraph (e. g. Risk and safety of advanced therapy).

The title will be written both in English and in Spanish.

### **5.3. Abstract (Second page)**

The abstract should not exceed 250 words for review and research articles summarizing the essential features of the article. The use of abbreviations should be reduced to a minimum and the references should not be cited in the abstract.

The abstract will be written both in English and in Spanish. In the case of foreign authors which do not manage Spanish language, the Editorial Office will be in charge of the corresponding translation.

### **5.4. Keywords (Second page)**

6 to 8 keywords must be provided separated by semicolon (;) in English and Spanish language.

### **5.5. Text Main and Organization (Third page and successive)**

Authors should present their materials with the utmost conciseness and clarity.

Text main may be divided into the following sections: 1. Introduction; 2. Materials and method; 3. Results and Discussion (or Results then Discussion); 4. Conclusions.

Subsections will be numbered as follows: 1.1. and successive 1.1.a. and successive.

The reference numbers should be given in brackets in the text. For example: (1) (2, 3) (2, 7, 9) (10-17). Italics should be used for Binomial names of organisms (Genus and Species), for emphasis and for unfamiliar words or phrases. Non-assimilated words from Latin or other languages should also be italicized *e.g. per se, et al. etc.*

Greek symbols and special characters often undergo formatting changes and get corrupted or lost during preparation of manuscript for publication. To ensure that all special characters used are embedded in the text, these special characters should be inserted as a symbol but should not be a result of any format styling (Symbol font face) otherwise they will be lost during conversion to PDF/XML. Chemical equations, chemical names, mathematical usage, unit of measurements, chemical and physical quantity & units must conform to International System of Units (SI) and Chemical Abstracts or IUPAC. All kinds of measurements should be reported only in SI.

## 5.6. List of Abbreviations

If abbreviations are used in the text either they should be defined in the text where first used, or a list of abbreviations can be provided.

## 5.7. Conflict of Interest

Financial contributions and any potential conflict of interest (if any) must be clearly acknowledged under the heading 'Conflict of Interest'.

## 5.8. Acknowledgements (if any)

This information must be included in the submitted manuscript as a separate paragraph under the heading 'Acknowledgements'. It will appear between the end of the bodytext and the reference list. Authors must list the source(s) of funding for the study. This should be done for each author.

## 5.9. References

References must be listed in the numerical system (Vancouver). All references should be numbered sequentially (**in brackets**) in the text and listed in the same numerical order in the reference section (**without brackets**). The bibliography must be fully formatted before submission.

See below few examples of references listed in the correct Vancouver style:

### Typical Paper Reference:

[1] Boehm M, Nabel EG. Angiotensin-converting enzyme 2-a new cardiac regulator. *N Engl J Med* 2002; 347: 1795-7.

[2] SoRelle R. Long reach of the N-terminal of B-type natriuretic peptide. *Circulation* 2002; 106: 9059-63.

[3] Leone A. Biochemical markers of cardiovascular damage from tobacco smoke. *Curr Pharm Des* 2005; 11: 2199-208.

[4] Meuillet EJ, Mahadevan D, Vankayalapati H, *et al.* Specific inhibition of the Akt1 pleckstrin homology domain by D-3-deoxyphosphatidyl- myo-inositol analogues. *Mol Cancer Ther* 2003; 2: 389-99.

### Typical Chapter Reference:

[5] Ban Y, Tomer Y. Endocrine diseases. Graves's and Hashimoto's diseases. In: Oksenberg J, Brassat D, Eds. Immunogenetics of autoimmune disease. Medical Intelligence Unit. New York: Landes Bioscience and Springer Science-Business Media 2006; pp. 41-58.

[6] Astrup P. The arterial wall in atherogenesis. In Cavallero Ed. Atherogenesis. Padua: Piccin Medical Books 1965; pp. 77-92.

**Book Reference:**

[7] Carlson BM. Human embryology and developmental biology. 3rd ed. St. Louis: Mosby 2004.

[8] Rosai J. Histological typing of tumours of the thymus. 2nd ed. Berlin and Heidelberg: Springer-Verlag 1999.

**Edited Book:**

[9] Brown AM, Stubbs DW, Eds. Medical physiology. New York: Wiley 1983.

**Conference Paper and Proceedings:**

[10] Kimura J, Shibasaki H, Eds. Recent advances in clinical neurophysiology. Proceedings of the 10th International Congress of EMG and Clinical Neurophysiology; 1995 Oct 15-19; Kyoto, Japan. Amsterdam: Elsevier 1996.

[11] Cooper R, Cutler J, Desvigne-Nickens P, *et al.* Disparities in coronary heart disease, stroke, and other cardiovascular diseases in the United States: findings of the National Conference on Cardiovascular Disease Prevention. *Circulation* 2000; 102: 3137-47.

[12] Chao JT, Theriault A, Gapor A. Delta-tocotrienol is a potent inhibitor of monocyte-endothelial cell adhesion. In: Cutting edge technologies For sustained competitiveness. Proceedings of the 2001 PI POC International palm Oil Congress, Food Technology and Nutrition Conference, Kuala Lumpur, Malaysia, Aug. 20-22, 2001; pp. 225-34.

**Journal Article on the Internet:**

[13] Aylin P, Bottle A, Jarman B, Elliott P. Paediatric cardiac surgical mortality in England after Bristol: descriptive analysis of hospital episode statistics 1991-2002. Available from: ([bmj.bmjournals.com/cgi/content/full/329/7470/825](http://bmj.bmjournals.com/cgi/content/full/329/7470/825)).

[14] NCT01013350. Prospective observational long-term safety registry of multiple sclerosis patients who have participated in cladribine clinical trials (PREMIERE). Available at ([clinicaltrials.gov/ct2/show/NCT01013350](http://clinicaltrials.gov/ct2/show/NCT01013350)).

**Book/Monograph on the Internet:**

[15] Donaldson MS, Ed. Measuring the quality of health care (monograph on the internet). Washington: National Academy Press 1999 (cited 2004 Oct 8). Available from: ([legacy.netlibrary.com](http://legacy.netlibrary.com)).

[16] Silva ATA. Ed. Development of compounds potentially active against *Helicobacter pylori*. Monograph on the internet. Araraquara: School of Pharmaceutical Science, Universidade Estadual Paulista 2008. Available from: ([www.fcfar.unesp.br/posgraduacao/](http://www.fcfar.unesp.br/posgraduacao/))



cienciasfarmaceuticas/Disertacoes/2008/antonio\_tavora-completo.pdf) monograph in Portuguese.

**Web site/Homepage:**

[17] HeartCentreOnline (homepage on the Internet). Boca Raton, FL: HeartCentreOnline, Inc.; c2000-2004. Available from: (www.heartcentralonline.com).

[18] Tuberculosis Antimicrobial Acquisition and Coordinating Facility (TAACF), Global discovery program for novel anti-tuberculosis drugs [homepage on the Internet]. The National Institute of Allergy and Infectious Diseases (NIAID). Available from: (www.taacf.org).

**Issue with Supplement:**

[19] Glauser TA. Integrating clinical trial data into clinical practice. *Neurology* 2002; 58(12 Suppl 7): S6-12.

[20] Durandy A, Kaveri SV, Kuijpers TW, *et al.* Intravenous immunoglobulins-- understanding properties and mechanisms. *Clin Exp Immunol* 2009; 158(Suppl 1): 2-13.

**Patent:**

Pagedas AC, inventor; Ancel Surgical R&D Inc., assignee. Flexible endoscopic grasping and cutting device and positioning tool assembly. United States patent US 20020103498. 2002 Aug.

Some important points to remember:

All references must be complete and accurate.

If the number of authors exceeds six then *et al.* will be used after three names (the term “*et al.*” should be in italics).

Journal names should be abbreviated according to the Index Medicus/MEDLINE in:

<http://www.ncbi.nlm.nih.gov/books/NBK3827/table/pubmedhelp.pubmedhelptable45/>

Superscript should be avoided.

**5.10. Appendices**

In case there is a need to present lengthy, but essential methodological details, use appendices, which can be a part of the article. An appendix must not exceed three pages and 900 max. words per page. The information should be provided in a condensed form, ruling out the need of full sentences. A single appendix should be titled APPENDIX, while more than one can be titled APPENDIX A, APPENDIX B, and so on.

**5.11. Supplementary Material**

This material will be available online in the [analesranf.com](http://analesranf.com) website. It should contain relevant and complementary data to those presented in the manuscript. Their format can be: tables, graphs, spectra, films and so on.

### **5.12. Figures**

Please make sure that artwork files are in an acceptable format and with the correct resolution.

**EPS (or PDF):** Vector drawings, embed all used fonts.

**TIFF (or JPEG):** Color or grayscale photographs (halftones), keep to a minimum of 300 dpi.

**TIFF (or JPEG):** Bitmapped (pure black & white pixels) line drawings, keep to a minimum of 1000 dpi.

**TIFF (or JPEG):** Combinations bitmapped line/half-tone (color or grayscale), keep to a minimum of 500 dpi.

If, together with your accepted article, you submit usable color figures they will appear in color on the Web.

Figures need to be cited along the text with Arabic numbers (Figure 1, Figure 2...), and the corresponding "Figure legends" need to appear after the reference list. These figure legends need a title and a brief self-explanation of their content, including color and simbol labels.

### **5.13. Tables**

Please submit tables as editable text and not as images. Tables can be placed either next to the relevant text in the article, or on separate page(s) at the end. Number tables consecutively in accordance with their appearance in the text and place any table notes below the table body. An interesting aspect to take into account is to ensure that the data presented in them do not duplicate results described elsewhere in the article.

Tables need to be cited along the text with Arabic numbers (Table 1, Table 2...).